Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Eisai's Apr-Dec Sales Down 17% on 50% Drop in Aricept Sales
February 3, 2012
- Pfizer to Offer Financial, Technical Support for Early Stage Development to External Institution
February 3, 2012
- Apr-Dec Sales Up 4%, Profits Show 2-Digit Increase due to Growth in Vesicare: Astellas
February 3, 2012
- Chugai to Restructure Marketing Div. to Achieve Targets in “Sunrise 2012” Plan
February 3, 2012
- New Granule Formulation of Fosrenol Obtains Approval: Bayer Yakuhin
February 3, 2012
- Janssen Files Application for Additional Subcutaneous Administration of Velcade
February 2, 2012
- Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO
February 2, 2012
- Astellas, UCB Form Partnership for Rheumatoid Arthritis Treatment Awaiting Approval
February 2, 2012
- Kyowa Kirin Sees Nesp as Core of Its Asian Strategy: President Matsuda
February 2, 2012
- Maruho, Asahi Kasei Pharma File Application for Add’l Indication of Herpes Simplex for Famvir
February 2, 2012
- Nycomed Acquisition Contributes to 4.3% Growth in Sales for April-December 2011: Takeda
February 2, 2012
- Daiichi Sankyo Says “No Major Impact” from Ranbaxy’s Relinquishment of Marketing Exclusivity
February 1, 2012
- Shuichi Watanabe to Become President, Sadatake Kumakura Chairman: Medipal HD
February 1, 2012
- Apr-Dec Net Profits Down 78% due to Ranbaxy Settlement Fee: Daiichi Sankyo
February 1, 2012
- Kyowa Hakko Kirin Withdraws Application for Additional Indication for Nesp
February 1, 2012
- Kyowa Kirin Development Chief Hanai Set to Become Company President
February 1, 2012
- Apr-Dec Sales Drop 1.2% due to Impact of Great East Japan Earthquake: MTPC
February 1, 2012
- Shared Awareness of Goals Needed in Industry-Academia Collaborations: Dr Teshirogi of Shionogi
February 1, 2012
- Patient Enrollment for All-case PMS for Imusera, Telavic Making Steady Progress: MTPC
February 1, 2012
- Mochida Pharmaceutical Sees Double-Digit Growth in Apr-Dec on Growth of Epadel
January 31, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…